FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2306653874> ?p ?o ?g. }

• W2306653874 endingPage "126" @default.
• W2306653874 startingPage "123" @default.
• W2306653874 abstract "This study provides preliminary evidence that risedronate not only preserves BMD but may also attenuate the loss of bone microarchitecture over 2 years during a time of accelerated bone loss in post-menopausal breast cancer survivors on aromatase inhibitors. Accelerated bone loss and elevated fracture risk are associated with the use of aromatase inhibitors (AIs) in women with breast cancer. We previously reported that the oral bisphosphonate, risedronate, can maintain bone mineral density (BMD) in the hip and spine over 2-years in post-menopausal breast cancer survivors on AIs. In this study, we examined whether oral bisphosphonates can also preserve bone microarchitecture as measured by the trabecular bone score (TBS) in this population. This 2-year randomized, double-blind, placebo-controlled trial included postmenopausal women over age 55 with breast cancer on an AI who had low bone mass. Participants provided informed consent and were randomized to risedronate 35 mg once weekly or placebo. We examined 12- and 24-month changes in spine TBS, analyzed using linear mixed models. One-hundred and nine women with a mean age of 70.5 years were included in the analysis. In the placebo group, BMD declined at the spine and hip over the 24-month period but was preserved in the active treatment group (data previously reported). TBS declined in the placebo group by − 2.1% and − 2.3% at 12- and 24-months, respectively (p < 0.005). The TBS percent change in bisphosphonate-treated patients was − 0.9% and − 1.3% at 12 and 24-months but did not reach statistical significance (p = 0.24 and 0.14). The 12- and 24-month between-group differences were 0.9 (p = 0.38) and 0.8 (p = 0.44) percentage points. TBS change correlated with spine BMD changes in the placebo group at 12- and 24-months (r = 0.33 and 0.34, p < 0.01) but not in the active treatment group. The oral bisphosphonate risedronate preserves BMD and may attenuate loss of bone microarchitecture over 2 years during a time of accelerated bone loss in breast cancer survivors on AIs, but more definitive evidence is needed." @default.
• W2306653874 created "2016-06-24" @default.
• W2306653874 creator A5002068827 @default.
• W2306653874 creator A5015117381 @default.
• W2306653874 creator A5022192136 @default.
• W2306653874 creator A5024527435 @default.
• W2306653874 creator A5026891957 @default.
• W2306653874 creator A5027209040 @default.
• W2306653874 creator A5037280359 @default.
• W2306653874 creator A5044108002 @default.
• W2306653874 creator A5071496344 @default.
• W2306653874 creator A5073755681 @default.
• W2306653874 date "2016-09-01" @default.
• W2306653874 modified "2023-10-05" @default.
• W2306653874 title "Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial" @default.
• W2306653874 cites W1548081233 @default.
• W2306653874 cites W1864817521 @default.
• W2306653874 cites W1939179845 @default.
• W2306653874 cites W1983211249 @default.
• W2306653874 cites W1990030853 @default.
• W2306653874 cites W1993490449 @default.
• W2306653874 cites W1993572903 @default.
• W2306653874 cites W2000519574 @default.
• W2306653874 cites W2012316238 @default.
• W2306653874 cites W2016885980 @default.
• W2306653874 cites W2026976996 @default.
• W2306653874 cites W2036992214 @default.
• W2306653874 cites W2038060377 @default.
• W2306653874 cites W2055925669 @default.
• W2306653874 cites W2061172474 @default.
• W2306653874 cites W2077605862 @default.
• W2306653874 cites W2077814106 @default.
• W2306653874 cites W2081192416 @default.
• W2306653874 cites W2102265912 @default.
• W2306653874 cites W2107789045 @default.
• W2306653874 cites W2120940916 @default.
• W2306653874 cites W2151771709 @default.
• W2306653874 cites W2168637297 @default.
• W2306653874 cites W3191534584 @default.
• W2306653874 cites W4234497896 @default.
• W2306653874 doi "https://doi.org/10.1016/j.bone.2016.03.010" @default.
• W2306653874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27018037" @default.
• W2306653874 hasPublicationYear "2016" @default.
• W2306653874 type Work @default.
• W2306653874 sameAs 2306653874 @default.
• W2306653874 citedByCount "7" @default.
• W2306653874 countsByYear W23066538742017 @default.
• W2306653874 countsByYear W23066538742018 @default.
• W2306653874 countsByYear W23066538742021 @default.
• W2306653874 countsByYear W23066538742022 @default.
• W2306653874 countsByYear W23066538742023 @default.
• W2306653874 crossrefType "journal-article" @default.
• W2306653874 hasAuthorship W2306653874A5002068827 @default.
• W2306653874 hasAuthorship W2306653874A5015117381 @default.
• W2306653874 hasAuthorship W2306653874A5022192136 @default.
• W2306653874 hasAuthorship W2306653874A5024527435 @default.
• W2306653874 hasAuthorship W2306653874A5026891957 @default.
• W2306653874 hasAuthorship W2306653874A5027209040 @default.
• W2306653874 hasAuthorship W2306653874A5037280359 @default.
• W2306653874 hasAuthorship W2306653874A5044108002 @default.
• W2306653874 hasAuthorship W2306653874A5071496344 @default.
• W2306653874 hasAuthorship W2306653874A5073755681 @default.
• W2306653874 hasConcept C121608353 @default.
• W2306653874 hasConcept C126322002 @default.
• W2306653874 hasConcept C126894567 @default.
• W2306653874 hasConcept C141071460 @default.
• W2306653874 hasConcept C142724271 @default.
• W2306653874 hasConcept C168563851 @default.
• W2306653874 hasConcept C202061045 @default.
• W2306653874 hasConcept C204787440 @default.
• W2306653874 hasConcept C27081682 @default.
• W2306653874 hasConcept C2776343214 @default.
• W2306653874 hasConcept C2776541429 @default.
• W2306653874 hasConcept C2776886416 @default.
• W2306653874 hasConcept C2777251235 @default.
• W2306653874 hasConcept C2777425516 @default.
• W2306653874 hasConcept C2908647359 @default.
• W2306653874 hasConcept C2991744798 @default.
• W2306653874 hasConcept C530470458 @default.
• W2306653874 hasConcept C71924100 @default.
• W2306653874 hasConcept C99454951 @default.
• W2306653874 hasConceptScore W2306653874C121608353 @default.
• W2306653874 hasConceptScore W2306653874C126322002 @default.
• W2306653874 hasConceptScore W2306653874C126894567 @default.
• W2306653874 hasConceptScore W2306653874C141071460 @default.
• W2306653874 hasConceptScore W2306653874C142724271 @default.
• W2306653874 hasConceptScore W2306653874C168563851 @default.
• W2306653874 hasConceptScore W2306653874C202061045 @default.
• W2306653874 hasConceptScore W2306653874C204787440 @default.
• W2306653874 hasConceptScore W2306653874C27081682 @default.
• W2306653874 hasConceptScore W2306653874C2776343214 @default.
• W2306653874 hasConceptScore W2306653874C2776541429 @default.
• W2306653874 hasConceptScore W2306653874C2776886416 @default.
• W2306653874 hasConceptScore W2306653874C2777251235 @default.
• W2306653874 hasConceptScore W2306653874C2777425516 @default.
• W2306653874 hasConceptScore W2306653874C2908647359 @default.
• W2306653874 hasConceptScore W2306653874C2991744798 @default.
• W2306653874 hasConceptScore W2306653874C530470458 @default.

• next